Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Part B Demo Program Will Miss March 7 Start-Up Goal

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicare law set a 90-day deadline to begin the $500 mil. program to expand Medicare coverage of alternatives to physician-administered drugs. The law also offered confusing advice on how CMS should allocate the money.

You may also be interested in...



Medicare Part B Replacement Drug Demo To Be Administered By Caremark And Trailblazer

Caremark/AdvancePCS will administer the drug benefit for the oral chemotherapy demonstration, while South Carolina Blues subsidiary Trailblazer will handle enrollment, eligibility and education. CMS expects the demo to be enrolling patients by mid-July.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

Topics

UsernamePublicRestriction

Register

PS058676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel